[Chemical targeting of DNA and histone methylation in cancer: Novelties, hopes and promises]

Bull Cancer. 2019 Oct;106(10):823-833. doi: 10.1016/j.bulcan.2019.08.001. Epub 2019 Sep 12.

[Article in French]

Authors

Corentin Bon¹, Diane Erdmann¹, Ludovic Halby², Paola Barbara Arimondo³

Affiliations

¹ Institut Pasteur, UMR3523 CNRS, Department of Structural Biology and Chemistry, Epigenetic Chemical Biology, 75015 Paris, France; Université de Paris, Sorbonne Paris Cité, école Doctorale MTCI, 75006 Paris, France.
² Institut Pasteur, UMR3523 CNRS, Department of Structural Biology and Chemistry, Epigenetic Chemical Biology, 75015 Paris, France.
³ Institut Pasteur, UMR3523 CNRS, Department of Structural Biology and Chemistry, Epigenetic Chemical Biology, 75015 Paris, France. Electronic address: paola.arimondo@cnrs.fr.

PMID: 31522746
DOI: 10.1016/j.bulcan.2019.08.001

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use
Combined Modality Therapy / methods
DNA Methylation* / drug effects
DNA Methylation* / physiology
Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors
Enzyme Inhibitors / therapeutic use
Epigenesis, Genetic / genetics*
Histone Demethylases / antagonists & inhibitors
Histones / metabolism*
Humans
Molecular Targeted Therapy / methods
Neoplasms / diagnosis
Neoplasms / genetics*
Neoplasms / therapy*
Protein-Arginine N-Methyltransferases / antagonists & inhibitors

Substances

Antineoplastic Agents
Enzyme Inhibitors
Histones
Histone Demethylases
PRMT5 protein, human
Protein-Arginine N-Methyltransferases
EZH2 protein, human
Enhancer of Zeste Homolog 2 Protein